Ann: Kyocera completes Progenza Due Diligence, page-31

For those wondering what Kyocera is looking for with a proper commercial agreement with RGS, here's a good summary: link

Kyocera is already heavily engaged in osteoarthritis as they manufacture artificial joints (through their Japan Medical Materials Corporation) and are focused in adding pain management to their portfolio.
Their interest in stem cells research is well documented as they joined the Tsuji project for hair loss a few years ago.

Once the terms of the agreement between RGS and Kyocera are announced, not only will it be a financial milestone for RGS but most certainly a strong indication on which areas their future research will focus: for example treatments targeted to the joints post operation for knee or hip replacement.

It's exciting, as an investor, to see this small cap's value being recognized ahead of this announcement.